https://scholars.lib.ntu.edu.tw/handle/123456789/190072
Title: | Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus | Authors: | CHIA-HSUIN CHANG JOU-WEI LIN Wu, Li-Chiu Lai, Mei-Shu LEE-MING CHUANG |
Issue Date: | 2012 | Journal Volume: | 97 | Journal Issue: | 7 | Start page/Pages: | E1170-E1175 | Source: | The Journal of Clinical Endocrinology & Metabolism | Abstract: | Background: Hyperinsulinemia might be the mechanism leading to an increased cancer risk in patients with type 2 diabetes. The objective was to evaluate the association between oral insulin secretagogues, insulins, and cancer incidence. Methods: A total of 108,920 patients with newly diagnosed type 2 diabetes were identified from the Taiwan National Health Insurance claims database during the period from 1 January 2000 to 31 December 2000. As of 31 December 2007, patients with incident cancer were included as cases, and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratio (OR) and 95% confidence interval (CI) between antidiabetic medication and cancer incidence. Results: A total of 8,194 incident cancer cases and 32,776 diabetic controls were included. A significantly increased risk for overall cancer incidence was found for any use of insulin (OR, 1.97; 95% CI, 1.85-2.09) and glinides (OR, 1.16; 95% CI, 1.06-1.28). Significantly increased risks were found for first-and second-generation sulfonylureas (OR, 1.08; 95% CI, 1.01-1.15), but not for third-generation drug, glimepiride (OR, 1.00; 95% CI, 0.93-1.08). Use of insulin and glinides was associated with higher risks for liver, colorectal, lung, stomach, and pancreas cancer, whereas sulfonylurea was mainly associated with an increased risk of liver cancer. Conclusions: The results showed that sulfonylureas and glinides increased the risk for overall cancer, but to a lesser extent than insulin. Therapies that are associated with cancer risks certainly require further investigation. (J Clin Endocrinol Metab 97: E1170-E1175, 2012) |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/258953 http://ntur.lib.ntu.edu.tw/bitstream/246246/258953/1/index.html |
DOI: | 10.1210/jc.2012-1162 | SDG/Keyword: | 2,4 thiazolidinedione derivative; acetylsalicylic acid; alpha glucosidase inhibitor; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; glimepiride; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; insulin derivative; metformin; oral antidiabetic agent; oral insulin secretagogue derivative; sulfonylurea derivative; unclassified drug; aged; article; cancer incidence; cancer patient; cancer risk; cohort analysis; colorectal cancer; controlled study; diabetic patient; female; high risk patient; human; liver cancer; longitudinal study; lung cancer; major clinical study; male; monotherapy; non insulin dependent diabetes mellitus; pancreas cancer; priority journal; risk assessment; stomach cancer; Administration, Oral; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Neoplasms; Registries; Risk Factors; Sulfonylurea Compounds |
Appears in Collections: | 醫學系 |
File | Description | Size | Format | |
---|---|---|---|---|
index.html | 23.16 kB | HTML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.